Wire open Last filed CagriSema bone density data at ObesityWeek point to a calcitonin receptor role RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
RoutineREGNews

GLP 1 prescriptions for children in England reach hundreds including some under 12 FOI data show

NHS data obtained by The Guardian show 419 under 18s with a community GLP 1 prescription in 2025 to 2026, ten of them under 12. Hospital and private prescribing are not counted, and long term data in growing children remain thin.

Editorial illustration for the story: GLP 1 prescriptions for children in England reach hundreds including some under 12 FOI data show
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

FOI data obtained by The Guardian show 419 children in England received a community GLP 1 prescription in 2025 to 2026, ten under 12, and 341 in the four months to July 2026.

Why it matters

The count leaves out hospital, private and prison prescriptions, so the real number is higher, and evidence on years of use in growing children is still limited.

What's next

Detailed STEP Young results in children aged six to under 12 follow at ObesityWeek, while wider use below 12 in the UK would need licence and guidance changes.

GLP 1 prescriptions for children in England reached 419 young people under 18 in the 2025 to 2026 financial year, according to freedom of information data obtained by The Guardian. Ten of them were younger than 12. In just the four months to July 2026, 341 children received such a prescription, 15 of them under 12. The figures come from the NHS Business Services Authority and count only part of the picture, because private, hospital and prison prescriptions are left out.

What the GLP 1 prescriptions for children data show

The Guardian report, published on November 14 and written by Nicola Davis, rests on community prescriptions written in England and dispensed anywhere in the UK. The count is of children, not of prescriptions, a point the paper corrected on November 16 after an editing error. The data do not say which drug each child received or why. Some prescriptions may have been for type 2 diabetes rather than weight, since several of these medicines were first approved for blood sugar control. The pace looks faster this year: the four month figure of 341 is close to the full previous year total of 419. That suggests use is rising, although a short window and a narrow data source make the trend hard to judge with confidence.

The gaps in the data matter as much as the numbers. Specialist NHS clinics for children with severe obesity usually supply these drugs through hospital pharmacies, which this data set does not capture. Private prescribing is also missing, and one private clinic for children has said it treats more than 200 young patients with the injections, the Guardian reported. The true number of children on these drugs in England is therefore likely to be well above the official count. For context, the National Child Measurement Programme puts obesity at 10.7% of children aged four and five, rising to 22.8% by ages ten and eleven. Against that scale, even the highest estimate covers a small share of affected children.

Specialist clinics and the age question

Since 2021 the NHS has piloted Complications from Excess Weight clinics for children aged two to 16 with severe obesity. NHS England said in May that almost 6,500 children had been referred, including more than 400 under four, the Guardian reported. Only some of these clinics can fund GLP 1 drugs. Julian Hamilton-Shield, who works at the Bristol clinic, told the paper that children offered semaglutide there have usually not responded to diet advice and psychological support and often have other conditions, such as type 2 diabetes, sleep apnoea or liver disease. Dunia Ismail, a consultant paediatrician who runs another clinic, said teams have kept to age 12 so far but are looking at age eight and over once licences allow.

Dunia Ismail, a consultant paediatrician who runs another clinic, said teams have kept to age 12 so far but are looking at age eight and over once licences allow.

The lower age limit is under active debate. The Guardian noted that new World Health Organization guidance issued last month advises against obesity drugs for children under ten. At the same time, Novo Nordisk has reported the STEP Young trial of semaglutide in 165 children aged six to under 12 with obesity. In its STEP Young announcement, the company said the trial met its main goal at 68 weeks and that 40.4% of children on semaglutide no longer met the obesity definition, against none on placebo, in an analysis that assumes all children stayed on treatment. Novo said it saw no new safety concerns, including for growth and puberty.

What experts say about safety and long term use

Martin Whyte, a professor of metabolic medicine at the University of Surrey, told the Guardian that the number of prescriptions remains small next to the scale of childhood obesity. His main concern was how treatment is run. He said children who start these drugs should do so inside specialist services, with a long term plan and regular checks on growth, puberty, nutrition, mental health, eating behaviour and side effects. Two reasons stand behind that advice. Weight tends to come back when the drugs stop, a pattern shown in adult data and discussed in our story on stopping Wegovy and Mounjaro. And there is still little evidence on many years of use in children who are still growing.

The clinicians quoted also stressed that these are not drugs for children who are slightly heavy. Hamilton-Shield said the young people treated at his clinic have very high excess weight and often face stigma, low self esteem and missed school, and that losing weight on the drug can give them a sense of control for the first time. Ismail described obesity as a condition rather than a choice. Those views come from doctors who prescribe the drugs, so they reflect clinical experience rather than trial results. Eating behaviour checks matter here too, given concerns raised about eating disorder screening for people starting GLP 1 drugs at any age. The table below collects the main numbers in the report.

FigureNumberSource as reported
Children under 18 with a community GLP 1 prescription, 2025 to 2026419, including 10 under 12NHS Business Services Authority via FOI
Children with a prescription, four months to July 2026341, including 15 under 12NHS Business Services Authority via FOI
Referrals to Complications from Excess Weight clinicsalmost 6,500NHS England, May 2026
Obesity at ages four to five and ten to eleven10.7% and 22.8%National Child Measurement Programme
Children in the STEP Young trial165, aged six to under 12Novo Nordisk

What happens next for children and GLP 1 drugs

The figures arrive as the evidence for younger children is still forming. STEP Young detailed results were due at ObesityWeek 2026, and any move to widen use below age 12 in the UK would depend on licensing decisions by regulators and on guidance for the NHS. Ismail tied any move to younger ages to licence approval, so clinics are unlikely to act before regulators do. Better data would help as well. A count that included hospital, private and prison prescriptions, with the drug and the reason for each, would show how many children are treated and why. Without it, the debate over GLP 1 prescriptions for children rests on partial numbers and on the views of the clinicians involved.

For families, the practical message from the specialists is that these medicines belong in supervised care with long term follow up, not in unsupervised use. The drugs have known digestive side effects, and in growing children the effects on growth, puberty and eating behaviour need watching over years rather than months. Several of the adult concerns, such as weight regain after stopping, are likely to apply to children too. Questions about safety, regulation and the unapproved market are tracked on the Peptide Zone safety desk, which will follow any guidance or licence change that affects younger patients. This report is research news, not medical advice.

Conclusion

GLP 1 prescriptions for children in England are rising from a low base, with at least 419 young people treated in a year and some under 12, though the true total is higher because hospital and private prescribing are not counted. Specialists support use in carefully selected children with severe obesity inside specialist clinics. Long term data on growth and development remain thin, and regulators have yet to decide whether younger children should be included.

More from the wire

Same thread first, then the same desk.